Avanir Pharmaceuticals taps Rohan Palekar for CEO role

Alok Saboo In this week's Chutes and Ladders, Rohan Palekar was appointed CEO of Avanir Pharmaceuticals, Allan Shaw was named CFO at Syndax, and Dr. Craig Granowitz was named chief ...

Sanofi’s reportedly on the verge of ‘sizable’ job cuts as diabetes business sputters

Damian Garde French drugmaker Sanofi is soon to announce some "sizable" cuts to its payroll, according to Stat, part of new CEO Olivier Brandicourt's plot to engineer ...

Levaquin users slap J&J with $800M RICO suit, claiming pharma giant hid serious side effects

Emily Wasserman Johnson & Johnson is facing yet another lawsuit over its antibiotic Levaquin from people who claim that the company hid serious side effects tied to the drug. The ...

China’s Cocoon rolls out a $720M fund to back U.K. biotechs; AbbVie teams up with MD Anderson on immuno-oncology;

Alok Saboo FierceBiotech News

AstraZeneca chief chalks up milestones on his map to $45B

Tracy Staton AstraZeneca CEO Pascal Soriot summarizes his accomplishments at the U.K.-based pharma giant in two words–Lynparza and Tagrisso. FiercePharma News

FDA slaps Pfizer’s Hospira unit for ‘misleading’ YouTube ad

Beth Snyder Bulik In the first enforcement action from the FDA's marketing police this year, the Office of Prescription Drug Promotion put Hospira in the hot seat ...

FDA bans products from China plant used by Big Pharma players

Emily Wasserman A Chinese ingredient maker who has produced ingredients for some of the big guns in pharma including Novartis, Sanofi and Pfizer is getting its products banned by the ...

Galapagos moves AbbVie-partnered drug into PhI as multipronged attack on CF takes shape

Nick Paul Taylor Galapagos has kicked off a Phase I trial of its AbbVie-partnered cystic fibrosis (CF) drug, GLPG2222. The start of the trial marks another milestone in the rolling ...

UCL sets up £50M VC fund to support academic spinouts

Nick Paul Taylor University College London (UCL) is getting into the venture capital game. The university, which has spawned a host of biotechs, has rounded up £50 million ($ ...

BMS, Lilly, Sanofi and Novartis top Big Pharma’s growth fortunes for next decade: Analysts

Tracy Staton Predicting the future–particularly when it comes to Big Pharma's prospects for growth and earnings–is a favorite pastime among industry-watchers. Even better ...

Novartis extends lead on psoriasis rivals with a pair of new Cosentyx approvals

Carly Helfand Novartis has been working hard to rack up indications for new med Cosentyx before other next-gen psoriasis competitors hit the scene. And now, it's accomplished that ...

GAO report hammers FDA for lax oversight on speedily approved drugs

Carly Helfand These days, the FDA is approving more and more drugs under its expedited programs, meaning new treatments are getting to patients faster. The problem? The agency ...
Page 2 of 20412345...102030...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS